AS
Altshuler Shaham Portfolio holdings
AUM
$3.14B
1-Year Return
24.55%
This Quarter Return
+0.13%
1 Year Return
+24.55%
3 Year Return
+51.84%
5 Year Return
+71.45%
10 Year Return
–
AUM
$2.38B
AUM Growth
+$188M
(+8.6%)
Cap. Flow
+$184M
Cap. Flow
% of AUM
7.72%
Top 10 Holdings %
Top 10 Hldgs %
79.65%
Holding
420
New
125
Increased
152
Reduced
62
Closed
60
Top Buys
| 1 |
Cisco
CSCO
|
$62.8M |
| 2 |
Palo Alto Networks
PANW
|
$45.1M |
| 3 |
Fortinet
FTNT
|
$33.4M |
| 4 |
Check Point Software Technologies
CHKP
|
$30.7M |
| 5 |
iShares MSCI South Korea ETF
EWY
|
$30M |
Top Sells
| 1 |
Builders FirstSource
BLDR
|
$29.5M |
| 2 |
Alibaba
BABA
|
$27.1M |
| 3 |
ICL Group
ICL
|
$9.98M |
| 4 |
Elbit Systems
ESLT
|
$3.97M |
| 5 |
International Flavors & Fragrances
IFF
|
$2.06M |
Sector Composition
| 1 | Technology | 31.7% |
| 2 | Consumer Discretionary | 16.23% |
| 3 | Industrials | 7.87% |
| 4 | Real Estate | 4.08% |
| 5 | Healthcare | 1.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MESO
251
Mesoblast
MESO
$1.84B
| $16K | ﹤0.01% |
425
| – | – |
|
252
Morningstar
MORN
$10.8B
| $16K | ﹤0.01% |
+113
| New | +$16K |
|
|
ADAM
253
Adamas Trust, Inc. Common Stock
ADAM
$669M
| $16K | ﹤0.01% |
634
-29
| -4% | -$732 |
|
254
Pegasystems
PEGA
$9.5B
| $16K | ﹤0.01% |
+460
| New | +$16K |
|
255
RingCentral
RNG
$2.89B
| $16K | ﹤0.01% |
+136
| New | +$16K |
|
|
RWT
256
Redwood Trust
RWT
$823M
| $16K | ﹤0.01% |
972
-28
| -3% | -$461 |
|
|
TRTX
257
TPG RE Finance Trust
TRTX
$761M
| $16K | ﹤0.01% |
806
+20
| +3% | +$397 |
|
|
ZNGA
258
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $15K | ﹤0.01% |
2,527
+396
| +19% | +$2.35K |
|
259
Mesa Laboratories
MLAB
$356M
| $13K | ﹤0.01% |
52
-150
| -74% | -$37.5K |
|
260
Steris
STE
$24.2B
| $13K | ﹤0.01% |
+84
| New | +$13K |
|
261
ANI Pharmaceuticals
ANIP
$2.07B
| $12K | ﹤0.01% |
+142
| New | +$12K |
|
262
CorVel
CRVL
$4.39B
| $12K | ﹤0.01% |
399
+27
| +7% | +$812 |
|
263
Glaukos
GKOS
$5.39B
| $12K | ﹤0.01% |
153
-130
| -46% | -$10.2K |
|
264
NovoCure
NVCR
$1.37B
| $12K | ﹤0.01% |
186
-206
| -53% | -$13.3K |
|
265
Teleflex
TFX
$5.78B
| $12K | ﹤0.01% |
35
+8
| +30% | +$2.74K |
|
266
Veracyte
VCYT
$2.55B
| $12K | ﹤0.01% |
434
+29
| +7% | +$802 |
|
|
VAR
267
DELISTED
Varian Medical Systems, Inc.
VAR
| $12K | ﹤0.01% |
90
-50
| -36% | -$6.67K |
|
268
Agilent Technologies
A
$36.5B
| $11K | ﹤0.01% |
150
-88
| -37% | -$6.45K |
|
269
Abbott
ABT
$231B
| $11K | ﹤0.01% |
131
-112
| -46% | -$9.41K |
|
270
Baxter International
BAX
$12.5B
| $11K | ﹤0.01% |
134
+29
| +28% | +$2.38K |
|
271
Bio-Rad Laboratories Class A
BIO
$8B
| $11K | ﹤0.01% |
+35
| New | +$11K |
|
272
Boston Scientific
BSX
$159B
| $11K | ﹤0.01% |
261
-210
| -45% | -$8.85K |
|
273
Chemed
CHE
$6.79B
| $11K | ﹤0.01% |
30
+6
| +25% | +$2.2K |
|
274
Cooper Companies
COO
$13.5B
| $11K | ﹤0.01% |
132
+24
| +22% | +$2K |
|
275
Quest Diagnostics
DGX
$20.5B
| $11K | ﹤0.01% |
+105
| New | +$11K |
|